Dark Remedy: The Impact of Thalidomide and its Revival as a Vital Medicine
Martin Schulz · BMJ · 2001
Trent Stephens, Rock Brynner Perseus Publishing, £18.99, pp 228 ISBN 0 7382 0404 8 Rating: ![Graphic][1] ![Graphic][2] ![Graphic][3] In 1982, when I was a graduate student at the Institute of Pharmacology at the University of Hamburg, I became personally involved with thalidomide (by that time better known in Germany as Contergan) for the first time. Of course, during university training every medical and pharmacy student learned that the so called Contergan disaster was the driving force behind a drug approval process that was concerned with both efficacy and, most importantly, safety. However, what lasts forever is the … [1]: /embed/inline-graphic-1.gif [2]: /embed/inline-graphic-2.gif [3]: /embed/inline-graphic-3.gif